Summary & Overview
HCPCS Q9993: Triamcinolone Acetonide Extended-Release Injection, 1 mg
HCPCS Level II code Q9993 denotes a preservative-free, extended-release, microsphere formulation of triamcinolone acetonide, 1 mg, intended for therapeutic injectable use. The code identifies a specific corticosteroid product used to deliver sustained local anti-inflammatory effects, typically administered in outpatient settings such as physician offices, ambulatory surgical centers, and hospital outpatient departments. Nationwide, product-specific HCPCS codes matter for accurate billing, product tracking, and payer policy alignment for specialty injectable medications.
Key payers included in this review are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for the formulation and likely sites of care, plus what to expect in payer coverage discussions: product identification for medical necessity reviews, billing and coding clarity for service lines that administer injections, and benchmarking considerations for utilization and reimbursement. The publication highlights areas where payers may apply prior authorization, coverage limits, or pathway requirements for extended-release corticosteroid injections.
This summary supplies national-level context, policy-relevant points for payers and providers, and pointers to operational considerations such as service line implications and typical sites of service. Data not available in the input: specific payer policies, common modifiers, associated taxonomies, ICD-10 diagnoses, related codes, and service line details.
Billing Code Overview
HCPCS Level II code Q9993 represents an injection of triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg. This product is a corticosteroid preparation formulated for extended intra-articular or soft-tissue delivery to provide sustained anti-inflammatory effect.
-
Service type: Therapeutic injectable corticosteroid
-
Typical site of service: Ambulatory surgical centers, outpatient clinics, physician offices, and hospital outpatient departments
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with moderately to severely symptomatic osteoarthritis of the knee presents to an orthopedic clinic for localized intra-articular corticosteroid therapy. The patient reports several months of persistent knee pain limiting ambulation and activities of daily living despite physical therapy, oral analgesics, and topical anti-inflammatories. The treating orthopedic surgeon (or pain management physician) evaluates the knee, documents focal joint line tenderness, crepitus, reduced range of motion, and radiographic evidence of osteoarthritic change.
The clinical workflow for administration of Q9993 (triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg) typically includes: a focused history and physical exam; review of contraindications (active joint infection, hypersensitivity, systemic infection); informed consent discussing risks and expected duration of effect; aspiration of the joint if effusion is present; ultrasound-guided or landmark-guided intra-articular injection performed under aseptic technique; documentation of drug name, strength, lot number, route, laterality, and patient response in the medical record; and post-procedure observation for immediate adverse events. Follow-up is scheduled to assess pain relief and functional improvement and to determine need for repeat intervention or alternative therapies.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure |